PharmaMar is the world leader biopharmaceutical company of the Zeltia Group, committed to advancing the treatment of cancer through the discovery and development of new marine-derived medicines.
PharmaMar has four novel compounds: Yondelis® has received Authorization for Commercialization from the European Commission for advanced soft tissue sarcoma, after failure of anthracyclines and ifosfamide, or who are unsuited to receive these agents.
Yondelis® is also in phase III for ovarian cancer and phase II for prostate, breast and paediatric cancers. Aplidin®, Zalypsis® and PM02734 are in clinical trials. PharmaMar also has a rich pipeline of preclinical candidates, and a strong R&D programme.
PharmaMar has wide experience in research of natural compounds and can contribute with a solid team working on natural product chemistry as well as with experience in the development of new anticancer drugs.
Also, PharmaMar has a proprietary and unique collection of more than 45000 classified marine samples collected all around the world, and experience in screening techniques for the detection of antiumor activity. Both collections, crude samples and pure compounds, can be shared for the search of antimetastatic compounds.